Noxopharm reports anti-cancer effects of Veyonda
Sydney anti-cancer treatment company Noxopharm (ASX: NOX) has reported anti-cancer effects of its Veyonda treatment in a small group of patients suffering advanced prostate cancer. The 14 patients’ cancers were metastatic and they had exhausted all treatment options when given Veyonda in association with low-dosage radiation in a single lesion. After six months, cancer progression…
Details